{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"580","upperLimit":"1500","value":"1000"},{"groupId":"OG001","lowerLimit":"750","upperLimit":"1200","value":"970"},{"groupId":"OG002","lowerLimit":"190","upperLimit":"620","value":"470"},{"groupId":"OG003","lowerLimit":"79","upperLimit":"510","value":"140"},{"groupId":"OG004","lowerLimit":"70","upperLimit":"250","value":"72"},{"groupId":"OG005","lowerLimit":"56","upperLimit":"240","value":"200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"Free APRIL target engagement (AUEC1-15d)"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"BCMA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"Biomarkers such as soluble a proliferation inducing ligand (APRIL; TNFSF13); soluble B cell maturation antigen (BCMA; TNFRSF17)","dispersionType":"Full Range","groups":[{"description":"50 mg BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.","id":"OG000","title":"BION-1301 50 mg Q2W"},{"description":"150 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG001","title":"BION-1301 150 mg Q2W"},{"description":"450 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG002","title":"BION-1301 450 mg Q2W"},{"description":"1350 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG003","title":"BION-1301 1350 mg Q2W"},{"description":"2700 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG004","title":"BION-1301 2700 mg Q2W"},{"description":"1350 mg BION-1301 will be administered as an IV infusion once per week for up to 8 weeks, followed by dosing once every 2 weeks.","id":"OG005","title":"BION-1301 1350 mg QW*8W->Q2W"}],"paramType":"MEDIAN","populationDescription":"Study was terminated early and Phase 2 did not enroll. BCMA was an exploratory endpoint and was not reported.","reportingStatus":"POSTED","timeFrame":"Baseline and approximately 2 years","title":"Biomarkers (Phase 1 and 2)","type":"PRIMARY","unitOfMeasure":"% change relative to baseline"}